FDA approval of VEPPANU is a major catalyst validating the PROTAC platform and providing a new revenue stream. Monitor for the announced third-party commercialization partner and initial sales figures post-launch. Given ARVN's low market cap (~$633M), upside potential is significant, but historical stock performance after positive news has been poor; consider profit-taking on initial pop if sustained.
Price Chart
Executive Summary
Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-mutated advanced breast cancer after prior endocrine therapy. The approval came ahead of the PDUFA date and is based on the VERITAC-2 trial showing a 43% reduction in risk of disease progression or death vs fulvestrant (HR 0.57). This transformative milestone validates the PROTAC platform and provides a new treatment option for a significant unmet need, though commercial execution and competition remain risks.
Key Facts
- First FDA-approved PROTAC therapy (VEPPANU/vepdegestrant), approved ahead of June 5, 2026 PDUFA date
- Indication: ER+/HER2- ESR1-mutated advanced or metastatic breast cancer after ≥1 line of endocrine therapy
- VERITAC-2 Phase 3 trial (N=270 ESR1m) showed median PFS 5 months vs 2.1 months for fulvestrant (HR 0.57, p=0.0001)
- Discovered by Arvinas, jointly developed with Pfizer; companies plan to select a third-party partner for commercialization
- Arvinas and Pfizer share worldwide development costs, commercialization expenses, and profits
Financial Impact
Transformative for ARVN as first approved drug; no specific revenue guidance provided. Partnership with Pfizer limits upside but reduces risk. Commercial potential depends on market adoption and third-party collaboration.
Risk Factors
- Commercial execution risk; vepdegestrant may face competition from existing endocrine therapies and CDK4/6 inhibitors
- Safety signals including QTc prolongation, liver enzyme elevations, and cytopenias could limit uptake
- Dependence on Pfizer partnership and third-party selection for commercialization
- Potential for slower-than-expected physician adoption or payer reimbursement challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286140 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access